Background Patients with atrial fibrillation who are vitamin K antagonist (VKA)-naive may
have a higher risk of thrombosis and/or bleeding than VKA-experienced patients. Methods …

Background Vitamin K antagonists are highly effective in preventing stroke in patients with
atrial fibrillation but have several limitations. Apixaban is a novel oral direct factor Xa …

Aims It is uncertain whether the benefit from apixaban varies by type and duration of atrial
fibrillation (AF). Methods and results A total of 18 201 patients with AF [2786 (15.3%) with …

Atrial fibrillation (AF) is associated with increased risk of stroke that can be attenuated with
vitamin K antagonists (VKAs). Vitamin K antagonist use is limited, in part, by the high …

Summary Background The Apixaban for Reduction in Stroke and Other Thromboembolic
Events in Atrial Fibrillation (ARISTOTLE) trial showed that apixaban is better than warfarin at …

Background—Apixaban is approved for the prevention of stroke and systemic embolism in
patients with nonvalvular atrial fibrillation. However, the Apixaban for Reduction in Stroke …

The ARISTOTLE trial showed a risk reduction of stroke/systemic embolism (SE) and major
bleeding in non-valvular atrial fibrillation (NVAF) patients treated with apixaban compared to …

Background Recent reports suggest an important contribution from frequent off-label use of
apixaban 2.5 mg twice daily to the higher rates of thromboembolic events observed in …

Aims We assessed the effect of concomitant aspirin use on the efficacy and safety of
apixaban compared with warfarin in patients with atrial fibrillation (AF). Methods and results …

Background Vitamin K antagonists have been shown to prevent stroke in patients with atrial
fibrillation. However, many patients are not suitable candidates for or are unwilling to receive …